To the full analysis
Sight Sciences stock: growth
SGHTSight Sciences reported $77.36M in revenue for fiscal 2025, down 3.1% on the prior year, up 22.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
39.5%
per year from 2018 to 2025, per share 30.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | 22.9% | 39.5% |
| Revenue per share | 20.2% | 30.2% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $7.53M | −$14.29M | −$15.05M |
| 2019 | $23.35M | −$25.87M | −$25.67M |
| 2020 | $27.64M | −$34.69M | −$33.13M |
| 2021 | $48.96M | −$62.96M | −$53.35M |
| 2022 | $71.33M | −$86.24M | −$76.94M |
| 2023 | $81.06M | −$55.55M | −$47.98M |
| 2024 | $79.87M | −$51.51M | −$22.74M |
| 2025 | $77.36M | −$38.43M | −$29.92M |
Revenue by segment
How Sight Sciences, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Surgical Glaucoma98%
- Dry Eye2%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Surgical Glaucoma | $46.5M | $65.59M | $74.31M | $75.9M | $75.72M | 97.9% |
| Dry Eye | $2.46M | $5.74M | $6.75M | $3.96M | $1.64M | 2.1% |
| Total revenue | $48.96M | $71.33M | $81.06M | $79.87M | $77.36M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.